- Home
- PAGP vs ACLX Comparison
PAGP vs ACLX Comparison
Compare PAGP & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$66.61
Company Overview
Basic Information| Metric | PAGP | ACLX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PAGP | ACLX |
|---|---|---|
| Price | $21.20 | $66.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $20.17 | ★ $113.75 |
| AVG Volume (30 Days) | ★ 2.1M | 887.5K |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | ★ 11.94 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $46,917,000,000.00 | $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.39 | $309.32 |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.61 | $47.86 |
| 52 Week High | $21.97 | $94.07 |
Technical Indicators
Market Signals| Indicator | PAGP | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 69.30 | 49.99 |
| Support Level | $20.08 | $66.46 |
| Resistance Level | $21.23 | $71.25 |
| Average True Range (ATR) | 0.40 | 3.18 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 86.58 | 23.00 |
Price Performance
Historical Comparison PAGP
ACLX
About PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.